Depemokimab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Depemokimab. Educational only — not medical advice.
Labeled uses
EXDENSUR is indicated for the add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. Limitations of Use EXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions (5.2 )] .
Source: FDA labeling via NIH DailyMed (set 30332b20…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.